Skip to main content
Brainsway Ltd. logo

Brainsway Ltd. — Investor Relations & Filings

Ticker · BWAY ISIN · IL0011007189 TA Manufacturing
Open in API
Filings indexed 375 across all filing types
Latest filing 2022-01-31 Regulatory Filings
Country IL Israel
Listing TA BWAY

About Brainsway Ltd.

https://www.brainsway.com/

Brainsway Ltd. is a medical technology company focused on developing and marketing advanced noninvasive neurostimulation treatments for mental health and addictive disorders. The company's core product is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system, which uses a patented H-coil to stimulate deeper and broader regions of the brain. The technology is designed as a safe and effective non-drug treatment option. The Deep TMS system has received multiple FDA clearances for conditions including Major Depressive Disorder (MDD), anxious depression, and Obsessive-Compulsive Disorder (OCD), for which it was the first noninvasive medical device to receive such clearance. It is also FDA-cleared as an aid for short-term smoking cessation, the first TMS device to be cleared for an addiction indication.

Recent filings

Filing Released Lang Actions
BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD
Regulatory Filings Classification · 1% confidence The document is very short (2083 characters) and explicitly states that it is an 'Immediate Report' under Israeli Securities Authority regulations. Crucially, the text ends with: "Attached hereto is a report on*BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS£ for the Treatment of OCD* *BrainsWay_Final_OCD_Palmetto_Medicare_LCD_isa.pdf*". This structure—a brief announcement stating that a specific report is attached or published—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is announcing the release of information rather than being the full report itself. Since it is a specific announcement about a regulatory/business update, RPA is more precise than the general fallback RNS.
2022-01-31 English
Adopted Resolutions of Annual General Meeting
AGM Information Classification · 1% confidence The document is explicitly titled 'FORM 6-K', which is a Report of Foreign Private Issuer filed with the SEC. The content section is titled 'Results of Annual Shareholder Meeting' and details the proposals approved at the AGM held on December 22, 2021, including the re-election of directors and approval of auditor compensation. Since this filing reports the results of the Annual General Meeting (AGM), the most specific classification is AGM Information (AGM-R). Although Form 6-K is a general regulatory filing, the specific content dictates the classification over the general 'RNS' fallback.
2021-12-23 English
Adopted Resolutions of Annual General Meeting
AGM Information Classification · 1% confidence The document explicitly states 'Adopted Resolutions of Annual General Meeting' and references an attached PDF file named 'December_22_2021_Results_of_Annual_General_Meeting_isa.pdf'. This content directly relates to the outcomes and resolutions passed during an Annual General Meeting. Although it is an announcement about the results, the core subject matter is the AGM resolutions, which aligns best with the AGM Information category (AGM-R). Given the short length and the mention of an attachment, it could potentially be RPA, but since the content is specifically about the *results* of the AGM, AGM-R is the most precise classification for the subject matter, even if it's presented as a filing announcement.
2021-12-23 English
BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is filed with the SEC by a Foreign Private Issuer (BrainsWay Ltd.) for the month of December 2021. Form 6-K is a general reporting requirement for foreign private issuers, often used to disseminate material information to the public that is not otherwise covered by specific SEC forms like 10-K or 10-Q. The core content is an announcement titled "BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects." This announcement details the results of a clinical trial and its presentation at a conference. Since this is an announcement of results, it fits best under the Earnings Release (ER) category if it were a periodic financial report, but since it is a specific, non-periodic announcement of clinical trial results being published, and it is filed on Form 6-K, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck. However, given the context of a press release announcing scientific/clinical findings, and the fact that Form 6-K is a catch-all for foreign issuers, RNS is the most suitable general regulatory fallback. It is not a full Annual Report (10-K), Interim Report (IR), or a dedicated Investor Presentation (IP) document format, but rather a press release filed via 6-K announcing a publication.
2021-12-09 English
BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects
Earnings Release Classification · 1% confidence The document is very short (2004 characters) and its primary function is to announce that a report/result has been published, explicitly stating: "Attached hereto is a report on *BrainsWay Announces Publication of Deep TMS� Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects*" and listing the attached file name. This structure—announcing the availability of a separate, substantive document—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself (like ER or IR), but the notice of its release. FY 2021
2021-12-09 English
OTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 22, 2021
AGM Information Classification · 1% confidence The document is explicitly titled "Appendix B - Form of Statement of a Candidate to Serve as a Director" and details the legal declarations required under Israeli Companies Law (Sections 224B, 226, 226A, 227) for a person seeking election to the Board of Directors. This statement is explicitly mentioned to be presented at the Annual General Meeting (AGM) where the election will be considered. While it relates to director qualifications, it is a specific legal form required for the election process, which is closely tied to the AGM and Board composition. Since the document is a formal statement/declaration required for director candidacy and is presented at the AGM, it aligns best with the context of Board/Management Information (MANG) or potentially Governance Information (CGR). However, given the focus on the *candidate's statement* for election, it is most directly related to the individuals serving on the board. If a specific code for Director Nomination/Qualification Statement existed, it would be used. Comparing the options, MANG covers 'Announcement of changes in the company's board of directors or senior management,' and this document is a prerequisite for *becoming* a director. CGR covers 'Governance Information' which includes board structure. Since this is a required legal document for a director candidate, it falls under the scope of governance and management structure documentation. Given the options, MANG is the most appropriate fit as it deals directly with the individuals who constitute the management/board.
2021-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.